Press Release



Santen releases *LENTIS*® *Comfort Toric* in Japan, a multifocal IOL covered under the Japanese health insurance program for cataract patients with astigmatism

November 5, 2020, Osaka, Japan -- Santen Pharmaceutical Co., Ltd. (Head office in Osaka; hereinafter "Santen") is pleased to announce the launch of *LENTIS® Comfort Toric* (LS-313 MF15 T1/T2/T3; hereinafter the "Product") in Japan. The Product is a multifocal intraocular lens (IOL) for cataract surgery, covered under Japan's national health insurance program and designed for patients with a certain level of corneal astigmatism.

This multifocal IOL is a variant of the multifocal IOL *LENTIS® Comfort* (LS-313 MF15), released in April 2019 and covered under the Japanese health insurance program, but has the added function for correcting corneal astigmatism. Similarly to *LENTIS® Comfort*, this Product has dual mono-focal structures combined in a unique fan-shaped design, and a relatively mild additional power* of 1.5 diopters to enable excellent intermediate and far distance vision, reduced ocular discomfort symptoms and extended depth of focus. Its ability to control astigmatism, which distorts vision, is expected to improve patients' post-surgery quality of visual function.

By providing *LENTIS*[®] *Comfort Toric* to the healthcare professionals as a new IOL option for cataract surgery, Santen will continue to enhance patients' vision, there by contributing to improving their quality of life.

*Added power to enable focus on near objects





LENTIS® Comfort Toric

IOL can be categorized into mono-focal IOL, which can only focus on a single point, and multifocal IOL, which can focus on multiple points for a broader range of vision correction.

Currently, *LENTIS*® *Comfort* and *LENTIS*® *Comfort Toric* are the only multifocal IOLs covered under Japan's health insurance program, capable of delivering excellent vision in both long distance and middle distance.

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (www.santen.com).

Contact

Akiko Yoshikawa Corporate Communications Group Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com Tel: +81-6-4802-9360